Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RestorAATion-1: SAD and MAD Study of WVE-006 in Healthy Participants
NCT06186492Phase 1Completed
- Sponsor
- Wave Life Sciences
- Start
- Nov 2023
- Primary completion
- Feb 2025
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of WVE-006 in alpha-1 antitrypsin deficiency (AATD) (7 arms), sponsored by Wave Life Sciences. Primary endpoint: Proportion of Participants With Adverse Events. Started Nov 2023; status: completed.
02
Drugs
WVE-006
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT06186492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06186492.